Blar i forfatter "Halvorsen, Tarje Onsøien"

Viser treff 1-7 av 7

    • Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT-1 trial 

      Horndalsveen, Henrik; Alver, Tine Norman; Dalsgaard, Astrid Marie; Helbekkmo, Nina; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Ramberg, Christina; Haakensen, Vilde Drageset; Øjlert, Åsa Kristina; Bjaanæs, Maria Moksnes; Helland, Åslaug; Rogg, Lotte Victoria (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-11-04)
      The introduction of immune checkpoint inhibitors has transformed the treatment landscape of metastatic non-small cell lung cancer. However, challenges remain to increase the fraction of patients achieving durable clinical responses to these drugs and to help monitor the treatment effect. In this phase II trial, we investigated the toxicity, systemic responses and circulating tumour DNA responses in ...

    • Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer 

      Halvorsen, Tarje Onsøien; Sundstrøm, Stein Harald; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Kaasa, Stein; Grønberg, Bjørn Henning (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-08-23)
      <b>Background:</b> Many patients with limited disease small cell lung cancer (LD SCLC) suffer from comorbidity. Not all patients with comorbidity are offered standard treatment, though there is little evidence for such a policy. The aim of this study was to investigate whether patients with comorbidity had inferior outcomes in a LD SCLC cohort. <br><b>Material and methods:</b> We analyzed patients ...

    • The prognostic effect of KRAS mutations in non-small cell lung carcinoma revisited: A norwegian multicentre study 

      Wahl, Sissel Gyrid Freim; Hong, Yan Dai; Emdal, Elisabeth Fritzke; Berg, Thomas; Halvorsen, Tarje Onsøien; Ottestad, Anine Larsen; Lund-Iversen, Marius; Brustugun, Odd; Førde, Dagny; Paulsen, Erna-Elise; Donnem, Tom; Andersen, Sigve; Grønberg, Bjørn Henning; Richardsen, Elin (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-08-26)
      Background: due to emerging therapeutics targeting KRAS G12C and previous reports with conflicting results regarding the prognostic impact of KRAS and KRAS G12C in non-small cell lung cancer (NSCLC), we aimed to investigate the frequency of KRAS mutations and their associations with clinical characteristics and outcome. Since mutation subtypes have different preferences for downstream pathways, we ...

    • Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy 

      Wahl, Sissel Gyrid Freim; Hong, Yan Dai; Emdal, Elisabeth Fritzke; Ottestad, Anine Larsen; Dale, Vibeke Grotnes; Richardsen, Elin; Halvorsen, Tarje Onsøien; Grønberg, Bjørn Henning (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-01-27)
      Droplet digital polymerase chain reaction (ddPCR) is a highly sensitive and accurate method for quantification of nucleic acid sequences. We used absolute quantification of mutated v‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homology gene (KRAS) by ddPCR to investigate the prognostic role of mutated KRAS in patients with KRAS‐mutated lung adenocarcinomas. Pre‐treatment plasma samples from 60 patients ...

    • Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer 

      Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Tollåli, Terje; Hornslien, Kjersti; Aksnessæther, Bjørg Y.; Liaaen, Erik Dyb; Sundstrøm, Stein Harald (Journal article; Tidsskriftartikkel; Peer reviewed, 2015-10-23)
      <br>BACKGROUND: <br> Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small cell lung cancer (LD SCLC). Twice daily TRT is well documented, but not universally implemented - probably mainly due to inconvenience and concerns about toxicity. A schedule of three-week hypofractionated TRT is a commonly used alternative. This is the first randomized trial ...

    • Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement 

      Valan, Christine Damgaard; Slagsvold, Jens Erik; Halvorsen, Tarje Onsøien; Herje, Martin; Bremnes, Roy M.; Brunsvig, Paal Fr.; Brustugun, Odd Terje; Fløtten, Øystein; Levin, Nina; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-02)
      Background/Aim: <br>There are several definitions of limited disease (LD) in small cell lung cancer (SCLC), differing with respect to N3 disease accepted. We analyzed patients from a randomized trial comparing two schedules of thoracic radiotherapy (TRT) in LD SCLC to investigate whether there were survival differences between N3 subcategories (n=144). Patients and <br>Methods: <br>Patients ...

    • Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer 

      Halvorsen, Tarje Onsøien; Herje, Martin; Levin, Nina; Bremnes, Roy M.; Brustugun, Odd Terje; Fløtten, Øystein; Kaasa, Stein; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-10-15)
      Objectives: <br> Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small-cell lung cancer (LD SCLC). TRT should start as early as possible, often meaning with the second course due to patient referral time and the fact that TRT planning takes time. Early assessment of response to the first course of chemotherapy may be a useful way to individualise treatment. ...